《新股消息》和黃醫藥(00013.HK)每股上市定價40.1元 集資總額逾41億元
長和(00001.HK)旗下生物醫藥公司和黃醫藥(00013.HK)(HCM.US)公佈,本港上市的的發售價已釐定爲每股發售股份40.1元(對比招股時指每股最高發售價或可達45元)。
假設超額配股權未獲行使,公司自全球發售獲得的所得款項總額(於扣除包銷費用及發售開支前)預期將爲41.704億港元。公司擬將全球發售的所得款項淨額用作推進其後期臨牀計劃以及其臨牀階段及臨牀前候選藥物管線、進一步增強其商業化、臨牀、監管及生產實力、爲潛在的全球業務發展及策略收購機會提供資金,以及用作一般企業用途。
和黃醫藥早前公佈計劃發售1.04億股股份,當中12.5%在港公開發售,餘下87.5%爲國際配售,每手500股,預計於6月30日上市。摩根士丹利、Jefferies及中金爲聯席保薦人。
和黃醫藥指其美國預託證券(每份代表五股股份)於納斯達克上市買賣,其美國預託證券於納斯達克的最新報價爲每份美國預託證券30.02美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.